Juvena Therapeutics | $33,500,000 | (Jan 14, 2026)
Allos | $5,000,000 | (Jan 14, 2026)
Nodu | $1,450,000 | (Jan 14, 2026)
Sparrow Pharmaceuticals, Inc.
United States
- Portland, Oregon
- 25/09/2025
- Series B
- $95,000,000
Sparrow Pharmaceuticals is a targeted cardiometabolic therapeutics company delivering improved outcomes for millions of patients who struggle to control their disease with current options for diabetes and related metabolic conditions.
The Company’s lead candidate, clofutriben, is a first-in-class, once-daily, oral HSD-1 inhibitor initially in development for type 2 diabetes with elevated cortisol. HSD-1 inhibition targets an underlying etiology of treatment resistance across the spectrum of metabolic dysfunction and is complementary to leading antidiabetic agents.
Sparrow is led by an experienced team of biotech executives, endocrinologists, and drug development veterans with a shared commitment to precision medicine in metabolic disease.
- Industry Pharmaceutical Manufacturing
- Website https://sparrowpharma.com/
- LinkedIn https://www.linkedin.com/company/sparrowpharma/
Related People
Robert JacksFounder
United States -
New York City Metropolitan Area
Biopharmaceutical industry executive with 25 years of experience focused on product development, corporate strategy, business development, fund raising, commercial analysis, finance, and operations. Multiple companies founded or co-founded. More than $300 million raised with several successful exits.
Cytotheryx, Inc. | $60,000,000 | (Jan 13, 2026)
MEDIPOST, Inc. | $140,000,000 | (Jan 13, 2026)
TRYBE | $30,000,000 | (Jan 13, 2026)
Diagonal Therapeutics | $125,000,000 | (Jan 13, 2026)
VelaFi | $20,000,000 | (Jan 13, 2026)
encoord | $2,000,000 | (Jan 13, 2026)
Avenue Biosciences | $7,500,000 | (Jan 13, 2026)
Unusual | $3,600,000 | (Jan 13, 2026)
BlueNalu | $11,000,000 | (Jan 13, 2026)